- Trial Phase
- Phase 3 (completed)
- Time to Market
- BLA submission planned for Q4 2026. If accepted and standard review, a PDUFA decision would likely ~6 months after submission, putting a potential approval in mid-2027.
- Why 7/10
- The next hard catalyst is the BLA submission for Zenkuda (tarcocimab tedromer) expected in Q4 2026 (within ~2 months). This is the company's lead asset driving most of the thesis, and the stock already surged ~178% on the Phase 3 data. The BLA submission is a regulatory filing milestone, not a binary approval decision, so impactScore is 7 rather than 8+.
Watch for the BLA submission for Zenkuda in Q4 2026 — the exact filing date and whether it covers wet AMD and/or diabetic retinopathy will be key. Monitor ATM sales pace via quarterly filings for dilution pressure. The next binary event after submission will be the PDUFA date assignment and eventual FDA decision (~6 months post-submission, likely mid-2027).
Price Chart
Executive Summary
Tarcocimab tedromer (proposed brand name Zenkuda, formerly KSI-301) is Kodiak Sciences' lead asset — an anti-VEGF antibody biopolymer conjugate for retinal diseases. The drug has completed five positive Phase 3 studies across wet AMD, diabetic retinopathy, and retinal vein occlusion, highlighted by the September 2026 DAYBREAK trial that met its primary endpoint of non-inferiority vs. aflibercept. The stock surged ~178% on that data. The next catalyst is the BLA submission expected in Q4 2026. With a Strong Buy analyst consensus, $121.67 mean price target (~39% upside), and a potential 6-month dosing advantage over current standards of care, the drug looks well-positioned. However, the company is pre-revenue with $125.9M cash, just filed a $350M ATM equity shelf, and faces entrenched competition from Regeneron's Eylea and Roche's Vabysmo.
How It Works
An anti-VEGF antibody biopolymer conjugate — a lab-made protein drug fused to a biocompatible polymer to make it last longer in the eye. It blocks VEGF, a protein that drives abnormal blood vessel growth and fluid leakage in the retina, which are the root causes of vision loss in wet age-related macular degeneration (wet AMD), diabetic retinopathy, and retinal vein occlusion. The polymer extension is designed to allow patients to go 6 months between injections, compared to current standard-of-care drugs that require monthly or every-2-month eye injections.
Trial Status
Tarcocimab tedromer has completed five positive Phase 3 studies across three retinal diseases. The pivotal Phase 3 DAYBREAK study in wet AMD (NCT06556368, 675 patients) met its primary endpoint in September 2026, showing non-inferior visual acuity gains versus aflibercept (Eylea) at one year. The Phase 3 GLOW2 study in diabetic retinopathy (NCT06270836, 255 patients) completed in February 2026 with positive topline results. Additional Phase 3 studies in retinal vein occlusion (BEACON) also met endpoints. The drug demonstrated consistent 6-month predominant durability and favorable safety across the program.
The Two-Sided Case
Upcoming Catalysts
- BLA submission for Zenkuda (tarcocimab tedromer) expected in Q4 2026
- Potential PDUFA date assignment following BLA acceptance (mid-2027 if accepted
- AAO 2026 data presentations of DAYBREAK detailed data (October 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Kodiak Sciences Inc. S-3ASR KOD ·Originating report